AG
DNLI icon

Algert Global’s Denali Therapeutics DNLI Stock Holding History

Algert Global’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-127,030
Closed -$2.1M – 1206
2025
Q4 		$2.1M Buy
127,030
+25,770
+25% +$435K 0.03% 702
2025
Q3 		$1.47M Buy
101,260
+15,420
+18% +$222K 0.02% 758
2025
Q2 		$1.2M Buy
+85,840
New +$1.21M 0.03% 765
2025
Q1 		– Sell
-39,015
Closed -$795K – 1211
2024
Q4 		$795K Sell
39,015
-9,615
-20% -$246K 0.02% 834
2024
Q3 		$1.42M Buy
48,630
+21,975
+82% +$545K 0.04% 678
2024
Q2 		$619K Sell
26,655
-55,345
-67% -$1.06M 0.02% 833
2024
Q1 		$1.68M Buy
+82,000
New +$1.54M 0.07% 468
2023
Q3 		– Sell
-16,097
Closed -$475K – 1144
2023
Q2 		$475K Hold
16,097
– – 0.02% 821
2023
Q1 		$371K Sell
16,097
-13,329
-45% -$367K 0.02% 895
2022
Q4 		$818K Buy
29,426
+21,792
+285% +$648K 0.05% 642
2022
Q3 		$234K Buy
+7,634
New +$248K 0.01% 1007
2022
Q2 		– Sell
-15,203
Closed -$489K – 1245
2022
Q1 		$489K Buy
15,203
+7,834
+106% +$270K 0.03% 820
2021
Q4 		$329K Hold
7,369
– – 0.04% 699
2021
Q3 		$372K Buy
+7,369
New +$415K 0.05% 668
2020
Q1 		– Sell
-30,974
Closed -$540K – 436
2019
Q4 		$540K Buy
+30,974
New +$516K 0.16% 196

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Algert Global's DNLI Position: Q1 2026 in Review

Algert Global sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 127,030 shares — an estimated $2.1M sold.

Algert Global first reported a position in DNLI in Q4 2019 and held it in 15 quarters. The position peaked at $2.1M in Q4 2025. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Algert Global reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Algert Global sold 127,030 Denali Therapeutics shares in Q1 2026, an estimated $2.1M.
  • Algert Global first reported a position in Denali Therapeutics in Q4 2019 and held it in 15 quarters.
  • Algert Global's Denali Therapeutics position peaked at $2.1M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.